Physician profile
Claudia Lam
NPI 1538858725
$717.13
in general payments reported to CMS, 2019-2025
10 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $28.99 · 2024: $384 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $313.03 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $92.30 | 2024-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $85.99 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $57.23 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $45.22 | 2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $38.50 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $28.99 | 2023 | Amvuttra |
| Hologic Sales and Service, LLC | $24.49 | 2024 | Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.07 | 2024 | Jardiance, Tradjenta |
| Pfizer INC. | $13.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.